Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Yu, Hui Chuan ^a   Hou, Duen Ren ^c   Liu, Chun Yu ^d   Lin, Chen Si ^b   Shiau, Chung Wai ^e   Cheng, Ann Lii ^a   Chen, Kuen Feng ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CALYCULIN A; CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; INITIATION FACTOR 4E BINDING PROTEIN 1; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEASOME; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ACRIDINE ORANGE; AUTOANTIGENS; AUTOPHAGY; BLOTTING, WESTERN; BORONIC ACIDS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PHOSPHATASE 2; PYRAZINES; TIME FACTORS;

EID: 84873273329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055705     Document Type: Article

References (50)

1. Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, et al. (2009) The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol 20 Suppl 7: vii1-vii6.
2. Rosenfeldt MT, Ryan KM, (2011) The multiple roles of autophagy in cancer. Carcinogenesis 32: 955-963.
3. Mathew R, Karantza-Wadsworth V, White E, (2007) Role of autophagy in cancer. Nat Rev Cancer 7: 961-967.
4. Eskelinen EL, (2005) Doctor Jekyll and Mister Hyde: autophagy can promote both cell survival and cell death. Cell Death Differ 12 Suppl 2: 1468-1472.
5. Morselli E, Galluzzi L, Kepp O, Vicencio JM, Criollo A, et al. (2009) Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 1793: 1524-1532.
6. Roy S, Debnath J, (2010) Autophagy and tumorigenesis. Semin Immunopathol 32: 383-396.
7. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, et al. (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8: 333-338.
8. Adams J, (2002) Development of the proteasome inhibitor PS-341. Oncologist 7: 9-16.
9. Richardson PG, Hideshima T, Anderson KC, (2003) Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 10: 361-369.
10. Voorhees PM, Orlowski RZ, (2006) The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 46: 189-213.
11. Ling YH, Liebes L, Ng B, Buckley M, Elliott PJ, et al. (2002) PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1: 841-849.
12. Orlowski RZ, Kuhn DJ, (2008) Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657.
13. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, et al. (2008) Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 68: 9323-9330.
14. Zhu K, Dunner K Jr, McConkey DJ, (2010) Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29: 451-462.
15. Li C, Johnson DE, (2012) Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Lett 314: 102-107.
16. Jung CH, Ro SH, Cao J, Otto NM, Kim DH, (2010) mTOR regulation of autophagy. FEBS Lett 584: 1287-1295.
17. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
18. Mizushima N, (2010) The role of the Atg1/ULK1 complex in autophagy regulation. Curr Opin Cell Biol 22: 132-139.
19. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
20. Arico S, Petiot A, Bauvy C, Dubbelhuis PF, Meijer AJ, et al. (2001) The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 276: 35243-35246.
21. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, et al. (2006) Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 10: 51-64.
22. Degtyarev M, De Maziere A, Orr C, Lin J, Lee BB, et al. (2008) Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 183: 101-116.
23. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, et al. (2008) Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48: 83-90.
24. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, et al. (2008) Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68: 6698-6707.
25. Bielinski VA, Mumby MC, (2007) Functional analysis of the PP2A subfamily of protein phosphatases in regulating Drosophila S6 kinase. Exp Cell Res 313: 3117-3126.
26. Eichhorn PJ, Creyghton MP, Bernards R, (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta 1795: 1-15.
27. Perrotti D, Neviani P, (2008) Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 27: 159-168.
28. Van Hoof C, Goris J, (2003) Phosphatases in apoptosis: to be or not to be, PP2A is in the heart of the question. Biochim Biophys Acta 1640: 97-104.
29. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, et al. (2009) Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 284: 11121-11133.
30. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, et al. (2005) The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 8: 355-368.
31. Junttila MR, Li SP, Westermarck J, (2008) Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival. FASEB J 22: 954-965.
32. Junttila MR, Puustinen P, Niemela M, Ahola R, Arnold H, et al. (2007) CIP2A inhibits PP2A in human malignancies. Cell 130: 51-62.
33. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, et al. (2010) CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 10: 694-699.
34. Come C, Laine A, Chanrion M, Edgren H, Mattila E, et al. (2009) CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15: 5092-5100.
35. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, et al. (2011) CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 18: 857-865.
36. Khanna A, Bockelman C, Hemmes A, Junttila MR, Wiksten JP, et al. (2009) MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101: 793-805.
37. Qu W, Li W, Wei L, Xing L, Wang X, et al. (2010) CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol.
38. Vaarala MH, Vaisanen MR, Ristimaki A, (2010) CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29: 136.
39. Wang J, Li W, Li L, Yu X, Jia J, et al. (2011) CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 33: 290-298.
40. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, et al. (2010) CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29: 6257-6266.
41. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, et al. (2009) Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 16: 87-93.
42. Korolchuk VI, Menzies FM, Rubinsztein DC, (2009) A novel link between autophagy and the ubiquitin-proteasome system. Autophagy 5: 862-863.
43. Korolchuk VI, Menzies FM, Rubinsztein DC, (2010) Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 584: 1393-1398.
44. Kirkin V, McEwan DG, Novak I, Dikic I, (2009) A role for ubiquitin in selective autophagy. Mol Cell 34: 259-269.
45. Ding WX, Ni HM, Gao W, Yoshimori T, Stolz DB, et al. (2007) Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 171: 513-524.
46. Korolchuk VI, Mansilla A, Menzies FM, Rubinsztein DC, (2009) Autophagy inhibition compromises degradation of ubiquitin-proteasome pathway substrates. Mol Cell 33: 517-527.
47. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N, (1998) 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12: 502-513.
48. Sonenberg N, Gingras AC, (1998) The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 10: 268-275.
49. Balakumaran BS, Porrello A, Hsu DS, Glover W, Foye A, et al. (2009) MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 69: 7803-7810.
50. Li Y, Yue P, Deng X, Ueda T, Fukunaga R, et al. (2010) Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia 12: 848-855.